Piper Jaffray conducted an insulin delivery survey in November consisting of 140 patients, physicians and certified diabetes educators, analysts led by JP McKim tell investors in a research note. The firm’s top three takeaways from the survey are that the introduction of automated insulin delivery systems will increase pump penetration from ~30% today up into the 40%-45% range, Tandem Diabetes (TNDM) is gaining market share from Medtronic (MDT) though both are going to benefit from the Animas exit, and smart pens are more attractive to current multiple daily injection users compared to those already on a pump. Piper keeps Overweight ratings on both Insulet (PODD) and Tandem given this backdrop. It believes near term upside remains the highest for Tandem.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.